Title:
TGF-BETA SUPERFAMILY TYPE I AND TYPE II RECEPTOR HETEROMULTIMERS AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/067873
Kind Code:
A3
Abstract:
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.
Inventors:
KUMAR RAVINDRA (US)
GRINBERG ASYA (US)
SAKO DIANNE (US)
CASTONGUAY ROSELYNE (US)
GRINBERG ASYA (US)
SAKO DIANNE (US)
CASTONGUAY ROSELYNE (US)
Application Number:
PCT/US2017/055420
Publication Date:
May 17, 2018
Filing Date:
October 05, 2017
Export Citation:
Assignee:
ACCELERON PHARMA INC (US)
International Classes:
A61P7/00; A61K38/43; A61P7/06; C07K16/46; C07K19/00
Domestic Patent References:
| WO2012058768A1 | 2012-05-10 | |||
| WO2016164089A2 | 2016-10-13 |
Foreign References:
| US20120149879A1 | 2012-06-14 | |||
| US20130171095A1 | 2013-07-04 | |||
| US20160039922A1 | 2016-02-11 | |||
| US20150283209A1 | 2015-10-08 | |||
| US20060223753A1 | 2006-10-05 | |||
| US20180057607A1 | 2018-03-01 |
Other References:
ESCOBAR-CABRERA, E. ET AL.: "Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function", ANTIBODIES, vol. 6, no. 2, 16 May 2017 (2017-05-16), pages 1 - 16, XP055483933
Attorney, Agent or Firm:
VARMA, Anita et al. (US)
Download PDF:
Previous Patent: DEVICES AND METHODS FOR SAMPLE ANALYSIS
Next Patent: VARIANT ACTRIIB PROTEINS AND USES THEREOF
Next Patent: VARIANT ACTRIIB PROTEINS AND USES THEREOF